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Welcome everyone to the 2020 Business Meeting of the American Physician Scientists Association (APSA). My name is
Abhik Banerjee, and I serve as the 2019–2020 President for the organization. As you are aware because of the COVID-
19 pandemic, we had been forced to cancel our 2020 Association of American Physician (AAP)/American Society for
Clinical Investigation (ASCI)/APSA Joint Meeting at the Fairmont Chicago, originally scheduled on April 3 to 5, 2020. The
safety of our membership is our top priority, and our organization is currently navigating through the aftermath of the
cancelled meeting. Despite not being able to facilitate an in-person meeting for trainees of all stages of their physician-
scientist career development, we are committed to continue to be the student physician-scientist’s leading voice for
improving educational opportunities, advancing patient-oriented research, and advocating for the future of translational
medicine. In keeping with our organization’s mission and based on several trainee requests, APSA has elected to provide
Annual Meeting–related content online via the GoToMeeting platform over the originally scheduled weekend. Despite the
rapidly changing public health crisis our country faces, our organization remains steadfast in our commitment to advocate
for trainees’ needs, and we hope you take advantage of the excellent programming our volunteers have coordinated over
these next two days. Over the past six years, I have had the privilege of […]
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Welcome everyone to the 2020 Busi-
ness Meeting of the American Physician 
Scientists Association (APSA). My name 
is Abhik Banerjee, and I serve as the 2019–
2020 President for the organization. As 
you are aware because of the COVID-19 
pandemic, we had been forced to cancel 
our 2020 Association of American Physi-
cian (AAP)/American Society for Clinical 
Investigation (ASCI)/APSA Joint Meeting 
at the Fairmont Chicago, originally sched-
uled on April 3 to 5, 2020. The safety of 
our membership is our top priority, and 
our organization is currently navigating 
through the aftermath of the cancelled 
meeting. Despite not being able to facil-
itate an in-person meeting for trainees of 
all stages of their physician-scientist career 
development, we are committed to contin-
ue to be the student physician-scientist’s 
leading voice for improving educational 
opportunities, advancing patient-oriented 
research, and advocating for the future of 
translational medicine. In keeping with 
our organization’s mission and based on 
several trainee requests, APSA has elected 
to provide Annual Meeting–related con-
tent online via the GoToMeeting platform 
over the originally scheduled weekend. 
Despite the rapidly changing public health 
crisis our country faces, our organization 
remains steadfast in our commitment to 
advocate for trainees’ needs, and we hope 
you take advantage of the excellent pro-
gramming our volunteers have coordinat-
ed over these next two days.
Over the past six years, I have had the 
privilege of volunteering with APSA, see-
ing initiatives grow and develop in parallel 
to my own graduate training experience. I 
vividly recall participating at my first Joint 
Meeting in 2014, anxious to present find-
ings from my first laboratory rotation while 
simultaneously cramming preparatory 
materials for my boards in between the 
keynote talks. Coming from a small pro-
gram, I was surprised by the amount of col-
lective support and camaraderie afforded 
by the tri-society meeting. I learned about 
new training opportunities and, important-
ly, for the first time in my training, did not 
feel alone. So easy it seems to fall into silos 
in the laboratory, without another peer or 
even a mentor to completely understand 
your career aspirations. It is not uncom-
mon for physician-scientist trainees to be 
constantly questioned or challenged for 
their career path decisions, as many of 
those in the audience can attest.
Perhaps as a result of writing one too 
many grant applications for the organi-
zation over the past six years, I recall cit-
ing Dr. Wyngaarden’s 1979 statement 
(and many derivatives thereof) that the 
physician-scientist is an endangered spe-
cies (1–5). It is not terribly surprising — 
the training and career pathway suffers 
numerous challenges, including extended 
(and extending) training phases, attrition 
at almost every step, and lack of diversity, 
among other limitations (3, 6–9). Given 
these challenges over the past 40 years, I 
would ask: why has the physician-scientist 
not gone the way of the dodo?
Recognizing the unique challeng-
es faced by physician-scientist trainees, 
APSA was established in 2003 by a group 
of trainees for trainees (10). Through 
continuous support from numerous part-
ner organizations, including the AAP and 
ASCI, APSA has grown in scope and mis-
sion. Now in its 17th year, APSA represents 
over 2100 members from over 110 insti-
tutions across the country, with members 
ranging from undergraduate students to 
junior faculty members.
Over the past year, our organization 
has made progress on several key initia-
tives. First, APSA aims to support a diverse 
and robust physician-scientist workforce, 
and in 2018, we established a Diversity 
Ad Hoc Committee to develop program-
ming to address the lack of representa-
tion within the training pipeline (11). With 
generous support from the Burroughs 
Wellcome Fund and in collaboration with 
several national organizations, including 
the American Medical Women’s Associ-
ation (AMWA), Building the Next Gener-
ation of Academic Physicians (BNGAP), 
the Clinician Investigator Trainee Asso-
ciation of Canada (CITAC), the Latino 
Medical Student Association (LMSA), and 
the Student National Medical Association 
(SNMA), among other partners, APSA 
hosted its first Physician-Scientist Train-
ee Diversity Summit in June 2019. The 
event employed human-centered design 
thinking with stakeholders from across the 
physician-scientist community to discuss 
best practices for recruitment, retention, 
and support for diverse investigators at all 
stages of their career development, and 
led to several publications (Figure 1 and 
refs. 12–14). Since the Diversity Summit, 
APSA’s Diversity Ad Hoc Committee has 
made progress on multiple fronts, includ-
ing developing a tool kit for local commu-
nity engagement, coordinating multiple 
interactive sessions on imposter syndrome 
and diversity, and even creating a Twitter 
chat to follow up with outcomes discussed 
at the Summit (#DiverseDoubleDocs).
In addition to diversity, APSA also 
seeks to address the “leaky pipeline” of 
physician-scientist training: in particular, 
how involvement in academic research 
decreases as postgraduates enter spe-
cialty and subspecialty clinical training, 
with some individuals never returning 
to research over the remainder of their 
careers (3, 4). Barriers for postgraduate 
trainees to pursue research include insuffi-
cient time, funding, and mentorship while 
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a few examples, our 2019–2020 Under-
graduate Mentorship Program had record 
participation, with over 458 mentors 
and 554 mentees (72.6% women, 38.2% 
underrepresented minorities, and 32.1% 
first-generation college students) (Figure 
3). With generous support from Burroughs 
Wellcome Fund and the Doris Duke Char-
itable Foundation, we raised funds to sup-
port travel for eight mentees to participate 
in the 2020 Annual Meeting prior to the 
COVID-19 pandemic. In addition to our 
mentorship program, we recognize the 
diversity of our membership, the diverse 
interests of our membership, and the 
diverse paths to becoming a physician-sci-
entist, and have established new partner-
ships with several professional societies, 
including Research!America, the Ameri-
can Association for Dental Research, and 
Medical Student Pride Alliance, among 
others. As a final highlight, we conduct-
ed an IRB-approved study examining the 
prevalence and perception of efficacy of 
clinical continuity strategies used by dif-
ferent dual-degree programs during grad-
uate training. We are excited to share some 
of the results of this study later in this Busi-
ness Meeting. As pointed out in last year’s 
address, this study was born from an APSA 
Institutional Representative’s (IR) request 
to learn about best practices from other 
idency wiki in 2015. Since that point, we 
have strengthened our relationship with 
PSTP and Research in Residency (RIR) 
directors by participating in annual discus-
sions at the Alliance for Academic Inter-
nal Medicine (AAIM) Research Pathways 
Directors Workshops and the Association 
of American Medical Colleges (AAMC) 
Graduate Research, Education and Train-
ing (GREAT) meetings, as well as hosting a 
well-attended Research Residency Direc-
tors’ Meeting at our Annual Meeting (15). 
There is still huge demand for resources 
and information related to these training 
pathways (Figure 2). To address this, over 
the past year we have established an inter-
active session series focused on applying 
to training programs within internal med-
icine and pediatrics, with upcoming ses-
sions planned for surgery and psychiatry. 
We are continuing to work closely with the 
AAMC and partner organizations, includ-
ing the Society for Pediatric Research 
(SPR), to increase transparency for the 
postgraduate physician-scientist program 
application process and to facilitate transi-
tioning to this next stage of training.
APSA also expanded its ongoing pro-
gramming over the 2019–2020 year, 
including supporting six regional meetings 
and three diversity professional network-
ing events across the country. Highlighting 
balancing clinical responsibilities, and as 
such, the transition from resident/fellow 
to independence is an especially vulner-
able time. Recognizing this particularly 
challenging time for trainees, APSA began 
a new Resident, Fellow, and Junior Facul-
ty Committee in 2019. Since its inception, 
the Committee has developed new post-
graduate programming for APSA region-
al meetings and the Annual Meeting, has 
coordinated an early career physician-sci-
entist research value unit survey to ask how 
deans and department heads incentivize 
research and discernable outcomes on fac-
ulty retention, and is currently developing 
a prospective longitudinal study of grad-
uating resident, fellow, and junior faculty 
to evaluate factors that facilitate research 
retention versus attrition.
Another “leaky” area of the physi-
cian-scientist training pipeline is the tran-
sition itself to postgraduate training (3, 
4). With so many different specialty and 
subspecialty training options available, 
including programs with or without pro-
tected research time or research tracks, 
and due to the lack of a clear definition of 
what a postgraduate Physician-Scientist 
Training Program (PSTP) is, APSA recog-
nized the need for a consolidated source 
of information for applicants and took 
the lead to develop a research track res-
Figure 1. 2019 Physician-Scientist Trainee Diversity Summit. Image of stakeholder participants from APSA’s Physician Scientist Trainee Diversity Summit, 
held on June 21 and 22, 2019. Participants included representatives from the NIH, Burroughs Wellcome Fund, AAP, ASCI, and AAMC, as well as associate deans 
of diversity, dual-degree program directors, invited faculty speakers, and current trainees. APSA seeks to organize a follow-up conference in summer 2021. 
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plexity of challenges in front of them, they 
are continuously willing to engage and 
confront these challenges because of the 
core belief that with time, effort, and luck, 
challenges can be overcome.
Physician-scientists are also willing to 
help and support one another. Recently, 
our organization reapplied for NIH R13 
grant funding, specifically to support trav-
el funds for trainees from underrepresent-
ed backgrounds to attend the 2021–2025 
Joint Meetings. Given the amount of mov-
I would instead focus my argument on the 
theme of resiliency (8, 9). Integral to resil-
iency, or the ability to confront setback and 
recover, is optimism, and I would argue 
that successful physician-scientists are, by 
definition, optimists. Physician-scientists 
employ the scientific method to improve 
the health outcomes of the global com-
munity, and despite setback after setback 
after setback, continue to follow this path-
way for the sake of their patients’ quality of 
life. Though they acknowledge the com-
trainees across the country (11). To the IRs 
in the audience, I will comment that your 
voice is respected and heard. APSA was 
established by trainees for trainees, and 
we will follow through. You are not alone. 
APSA is here to help.
To the crux of this address, why has 
the physician-scientist not gone extinct? 
While I do not mean to belittle the impor-
tance of government, philanthropic, and 
educational interventions by not exhaus-
tively listing each and every one of them, 
Figure 2. Physician-Scientist Training Program/Research in Residency (PSTP/RIR) question-and-answer panel from the 2019 AAP/ASCI/APSA Joint 
Meeting. APSA-coordinated question-and-answer panel between prominent PSTP/RIR directors and trainees at the 2019 AAP/ASCI/APSA Joint Meeting. 
The panel grew to standing room only and caused meeting organizers to make accommodations for multiple parallel question-and-answer sessions during 
the 2020 Joint Meeting prior to COVID-19 meeting cancellation. APSA will continue to facilitate communication between research-integrated postgraduate 
programs and trainees to improve the transparency of the application process.
Figure 3. Record participation in the APSA Undergraduate Mentorship Program. APSA Undergraduate Mentorship Program Mentee demographic infor-
mation from program inception through the 2019–2020 cohort. Demographic information includes total mentees (A), percentage of mentees self-identi-
fied as from underrepresented minority backgrounds (B), and mentees self-identified as female (C). Figure adapted with permission from data presented 
in Fox et al. in the JCI (22).
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roughs Wellcome Fund, the Doris Duke 
Charitable Foundation, and the Lasker 
Foundation, as well as for continuous sup-
port from the ASCI and the AAP.
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ity has ever seen, and as the COVID-19 
pandemic illustrates, physician-scientists 
are needed now more than ever (21). To 
respond to the words of a senior inves-
tigator, I ask the field to stop scaring the 
children, be tenacious, stand firm, and 
be boldly optimistic despite adversity. To 
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On behalf of the APSA Executive Coun-
cil, I welcome you to the 2020 APSA Busi-
ness Meeting and the 2020 Virtual APSA 
Annual Meeting (Figure 4). Thank you.
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ing parts for the application, I reached out 
to representatives from ASCI and AAP 
leadership, as well as members of our own 
Board of Directors, for support. Despite 
their busy schedules, every single individ-
ual I contacted without hesitation provid-
ed support for our application, from let-
ters of support to fully reviewing multiple 
iterations of our entire grant application. 
Whether it was out of a desire to mentor 
trainees or out of particular support for 
our grant application’s purpose, physi-
cian-scientists have an often understated 
willingness to help and address challenges 
bigger than them.
Concluding, from the discovery of the 
LDL receptor based on a striking clinical 
observation to the development of a highly 
specific small-molecule inhibitor of chron-
ic myelogenous leukemia and the devel-
opment of the first human gene therapy 
treatment for inherited retinal degenera-
tion and other discoveries too numerous to 
state, physician-scientists have pushed our 
understanding of human disease and have 
led the charge towards precision and tar-
geted treatment (16–20). As future physi-
cian-scientists in the era of CRISPR/Cas9 
targeting, modern computing, and numer-
ous other advances in technology, you are 
training and will practice in the most excit-
ing era of biomedical research human-
Figure 4. 2019–2020 APSA Executive Council. 
Image of 2019–2020 APSA Executive Council 
and Board of Directors from the organization’s 
leadership retreat on July 13 and 14, 2019. 
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Groover, Jose Rodrigues, Moshe Levi, Evan 
Noch, and Omar Toubat. Second row (left to 
right): Aylin Rodan, Lillian Zhang, Gina Calco, 
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pher Williams, and Robinna Lorenz. Third row 
(left to right): Trevor Hunt, Samantha Spellicy, 
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Mensah. Back row: Alex Waldman.
The Journal of Clinical Investigation   A P S A  P R E S I D E N T I A L  A D D R E S S
2 7 3 7jci.org   Volume 130   Number 6   June 2020
endocytosis. Nature. 1979;279(5715):679–685.
 18. Deininger MW, Druker BJ. Specific targeted 
therapy of chronic myelogenous leukemia with 
imatinib. Pharmacol Rev. 2003;55(3):401–423.
 19. Acland GM, et al. Gene therapy restores vision 
in a canine model of childhood blindness. Nat 
Genet. 2001;28(1):92–95.
 20. Bennett J. My career path for developing gene 
therapy for blinding diseases: the importance of 
mentors, collaborators, and opportunities. Hum 
Gene Ther. 2014;25(8):663–670.
 21. Xiong X, Chen M, Lim WA, Zhao D, Qi LS. CRIS-
PR/Cas9 for human genome engineering and 
disease research. Annu Rev Genomics Hum Genet. 
2016;17:131–154.
 22. Fox BM, Adami AJ, Hull TD. Reinforcing our 
pipeline: trainee-driven approaches to improv-
ing physician-scientist training. J Clin Invest. 
2018;128(8):3206–3208.
 12. Christophers B, Gotian R. Using admis-
sion statistics to encourage diverse appli-
cants to MD-PhD programs. J Clin Invest. 
2020;130(1):17–19.
 13. Turbeville H, Gotian R. Put participants first in 
conference design [guest column]. Nature. http://
www.nature.com/articles/d41586-019-02759-2. 
September 12, 2019. Accessed April 30, 2020.
 14. Groover S, Gotian R. Five ‘power skills’ 
for becoming a team leader. Nature. 
2020;577(7792):721–722.
 15. The GREAT Group. Advancing Biomedical 
Research Training. Washington, DC, USA: Asso-
ciation of American Medical Colleges; 2014.
 16. Goldstein JL, Brown MS. The clinical investigator: 
bewitched, bothered, and bewildered--but still 
beloved. J Clin Invest. 1997;99(12):2803–2812.
 17. Goldstein JL, Anderson RG, Brown MS. Coated 
pits, coated vesicles, and receptor-mediated 
ACD_06042014.pdf. Updated June 1, 2014. 
Accessed April 29, 2020.
 7. Zemlo TR, Garrison HH, Partridge NC, Ley TJ. The 
physician-scientist: career issues and challenges at 
the year 2000. FASEB J. 2000;14(2):221–230.
 8. Ley TJ, Rosenberg LE. Removing career obstacles 
for young physician-scientists -- loan-repayment 
programs. N Engl J Med. 2002;346(5):368–372.
 9. Ley TJ, Rosenberg LE. The physician-scientist 
career pipeline in 2005: build it, and they will 
come. JAMA. 2005;294(11):1343–1351.
 10. Nguyen FT. The birth of the American Physician 
Scientists Association — the next generation of 
Young Turks. J Clin Invest. 2008;118(4):1237–1240.
 11. Iness AN. Waiting to “make it” versus “making 
it happen”: empowering physician-scientists in 
training [2019 American Physician Scientists 
Association Presidential Address]. J Clin Invest. 
2019;129(12):5062–5065.
